The Food and Drug Administration granted Orphan Drug Designation to Moleculin Biotech Inc.'s (Nasdaq: MBRX) acute myeloid leukemia treatment Annamycin sending the stock price up 26 cents to close at $1.33.
Moleculin Biotech receives Orphan Drug Designation
March 22, 2017 at 17:17 PM EDT
